The global tuberculosis diagnostics market is expected to register a CAGR of nearly 4.5%, during the forecast period of 2018-2023.

According to the World Health Organization (WHO), about 10 million people are affected by tuberculosis, each year. Further, tuberculosis is the leading cause of death from a single infectious agent, ranking above HIV/AIDS. In addition, the WHO also states that the developing economies of Asia-Pacific, Africa, and Latin America account for the major burden related to tuberculosis, MDR TB, and TB associated with HIV, as of 2017. As per a 2017 report of the WHO, about 153,000 patients with MDR/rifampicin resistant (RR) TB were detected worldwide, in 2016.

The cost associated with tuberculosis diagnostics varies across laboratories and hospitals, globally. According to Unitaid, the use of GeneXpert MTB/RIF is primarily hampered owing to its high cost, particularly in the emerging markets. Further, China and India were among the countries that reflect higher costs of tests and increased expansion of the private sector. This is further linked with the unavailability of proper laboratory capacities.

Owing to the presence of a large, diversified patient population and high burden of tuberculosis, Asia-Pacific is expected to retain its market position, over the forecast period. Countries, such as India, China, Indonesia, and Afghanistan are among the top-priority countries for the control of communicable diseases, according to the WHO. China and India registered the highest number new cases of tuberculosis annually, followed by African and Latin American countries.